Akari Therapeutics

Akari Therapeutics is a clinical-stage biopharma company developing next-generation bi-functional antibody-drug conjugates for cancer treatment.

Its proprietary ADC platform centres on PH1, a novel spliceosome-modulating small molecule payload designed to disrupt RNA splicing in tumour cells and activate anti-tumour immune responses.

Lead candidate AKTX-101 targets the Trop2 receptor on solid tumours; AKTX-102 targets CEACAM5. The company also retains a complement inhibition asset, Nomacopan, previously in clinical evaluation for rare autoimmune conditions.